For the use of a Registered Medical Practitioner or a Hospital or a Laboratory

PONSTAPYX

Mefenamic Acid Tablets BP 250 mg

COMPOSITION :
Each uncoated tablet contains
Mefenamic acid BP 250 mg
Excipients Q.S.
Colour: Tartarazine

PHARMACOLOGICAL CLASSIFICATION :
Antipyretic and anti-inflammatory analgesics

PHARMACOLOGICAL ACTION :
Ponstapyx has anti-inflammatory activity and also antipyretic and analgesic properties. As analgesia it has a central as well as a peripheral action. Ponstapyx appears to owe those properties to its capacity to inhibit cyclo-oxygenase. Also it appears to antagonise certain effects of prostaglandins.

INDICATIONS :
The relief of mild to moderate pain arising from rheumatic conditions, soft-tissue injuries, other painful musculoskeletal conditions and dysmenorrhoea.
Treatment of post traumatic conditions such as pain, swelling and inflammation for a maximum period of 5 days.

CONTRA-INDICATIONS :
Sensitivity to mefenamic acid and other non-steroidal anti-inflammatory agents, with prostaglandin synthetase inhibiting activity. The possibility of cross-sensitivity among non-steroidal anti-inflammatory agents exists.
Ponstapyx is contra-indicated in patients with ulceration or inflammation of the gastro-intestinal tract. Epileptics. Patients with impaired hepatic functions.
Safety in pregnancy and lactation has not been established.

WARNINGS :
If diarrhoea or skin rash appear, use of Ponstapyx should be discontinued immediately.

DOSAGE AND DIRECTIONS FOR USE :
Ponstapyx must be taken with meals.
Ponstapyx should not be given for longer than 7 days.

Relief of mild to moderate pain: 500 mg three times a day.
Acute pain: An initial dosage of 500 mg, thereafter 250 mg every 6 hours.
Children
The dosage for children is 25 mg per kg body-weight daily, in divided doses.

6 months to 1 year:	One medicine measureful (5 mL)
2 years to 4 years:	Two medicine measuresful (10 mL).
5 years to 8 years:	Three medicine measuresful (15 mL).
9 years to 12 years:	Four medicine measuresful (20 mL).

The dose may be repeated as necessary, up to three times daily.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS :
The commonest adverse effects occurring with Ponstapyx are gastro-intestinal disturbances. Peptic ulceration and gastro-intestinal bleeding have also been reported. Headache, drowsiness, dizziness, nervousness, visual disturbances, and slight elevations in blood-urea have been reported. Acute hypersensitivity reactions (urticaria, bronchospasm, anaphylaxis) have occurred. Asthma may be precipitated. Skin rashes occur. Reported haematological effects include haemolytic anaemia, agranulocytosis, pancytopenia, thrombocytopenic purpura, and bone-marrow aplasia.
Ponstapyx should be used with caution in patients with impaired renal or liver function. It may enhance the effects of coumarin anticoagulants.
Ponstapyx is best avoided in elderly patients with dehydration or pre-existing renal disease.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT :
See "side-effects and special precautions".
Mefenamic acid has a marked tendency to induce tonic-clonic (grand mal) convulsions in overdosage.
Treatment is symptomatic and supportive.

STORAGE :
Store below 30°C. Protect from light and moisture.
Keep the medicine out of reach of children.

PRESENTATION :
100 Tablets

Marketed by:

PYXUS PHARMACEUTICALS PVT. LTD.
A/707, Mondeal Heights, Beside Novotel Hotel,
Nr. Iscon Square, S.G. Highway, Ahmedabad,
Gujarat- 380015 (India).